Skip to main content

Ascelia Pharma

Ascelia Pharma AB is a Swedish biopharmaceutical company developing orphan oncology drugs for specialized cancer treatments. The company focuses on developing diagnostic and therapeutic products, including its lead candidate Orviglance, an oral contrast agent for liver MRI scans in patients with kidney impairment. Revenue is primarily generated through research funding, licensing partnerships, and capital raises ahead of commercial market authorization. Core end markets serve hospital radiology departments, oncology clinics, and specialized renal care units globally. Ascelia Pharma occupies a distinct position in the European orphan drug sector through its targeted diagnostic imaging solutions. The company is headquartered in Malmö, Sweden, and its shares trade on the Nasdaq Stockholm exchange.

3 of the funds FundTelligence covers report a position in Ascelia Pharma.

Legal name
Ascelia Pharma AB
Sector
Health Care
Country
Sweden
Funds holding it
3

Funds holding Ascelia Pharma

Loading...